oneCureGEN operates a drug discovery platform that develops companion diagnostics and targeted anticancer therapies through biomarker discovery and validation, ensuring high treatment efficacy with reduced side effects. The company addresses the unmet medical needs of cancer patients by providing personalized treatment options tailored to specific biomarkers.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer patients face limited treatment options, often with significant side effects, due to the lack of therapies tailored to their specific cancer biomarkers. This results in unmet medical needs and a demand for personalized treatment strategies that can improve efficacy and reduce adverse effects.
Solution
oneCureGEN is developing targeted anticancer therapies and companion diagnostics, leveraging biomarker discovery and validation to personalize cancer treatment. Their platform aims to identify specific biomarkers in patients' tumors, enabling the selection of therapies most likely to be effective for their individual cancer profile. By focusing on biomarker-driven drug development, oneCureGEN seeks to improve treatment outcomes and minimize side effects, addressing the unmet needs of cancer patients who may not respond well to traditional therapies. The company's approach involves developing both novel anticancer drugs and the diagnostic tools necessary to identify the patients who will benefit most from those drugs. This integrated strategy ensures that patients receive the right treatment at the right time, maximizing the potential for successful outcomes.
Target Audience
The primary target audience includes cancer patients with unmet medical needs, oncologists seeking personalized treatment options, and pharmaceutical companies interested in biomarker-driven drug development.
Features
- Biomarker discovery and validation platform for identifying novel drug targets
- Development of companion diagnostics to identify patients most likely to respond to specific therapies
- Pipeline of targeted anticancer therapies designed to address unmet medical needs
- Focus on reducing side effects through personalized treatment approaches
- Development of VGLL1 항암제
- Development of HIF 분해 항암제